Docetaxel polarizes MDSCs toward M1-like phenotype and upregulates macrophages markers (CD86, MHC class II, and CD11c) in vivo and in vitro partly through an inhibition of STAT-3 in 4T1-Neu mammary cancer implants [135]. This evidence concerns the gene ERBB2 and breast cancer.